Corbus Pharmaceuticals Holdings, Inc. Stock
Stocks
CRBP
US21833P3010
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
03:28:25 04/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 11.42 USD | -0.52% |
|
+2.02% | +39.50% |
| 13/08 | Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating | MT |
| 07/08 | Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating | MT |
| Market Cap | 222M 191M 179M 164M 306M 20.99B 309M 2.12B 826M 10.73B 834M 816M 34.55B | P/E 2026 * |
-2.09x | P/E 2027 * | -2x |
|---|---|---|---|---|---|
| Enterprise Value | 222M 191M 179M 164M 306M 20.99B 309M 2.12B 826M 10.73B 834M 816M 34.55B | EV / Sales 2026 * |
200x | EV / Sales 2027 * | 92.5x |
| Free-Float |
98.8% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CRBP | Delayed | |
CBOE
| CRBP | Real-time | |
|
Tradegate
| 3371 | Real-time | |
|
Deutsche Boerse AG
| 3371 | Delayed | |
|
Börse Stuttgart
| 3371 | Delayed | |
|
Boerse Muenchen
| 3371 | Real-time |
Last Transcript : Corbus Pharmaceuticals Holdings, Inc.
| 1 day | -0.52% | ||
| 1 week | +2.02% | ||
| Current month | +4.08% | ||
| 1 month | +27.30% | ||
| 3 months | +53.86% | ||
| 6 months | +38.31% | ||
| Current year | +39.50% |
| 1 week | 10.39 |  | 11.6 |
| 1 month | 8.98 | | 11.6 |
| Current year | 7.12 | | 12.88 |
| 1 year | 7.12 | | 20.56 |
| 3 years | 3.03 | | 61.9 |
| 5 years | 2.11 | | 61.9 |
| 10 years | 2.11 | | 323.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 51 | 11/04/2014 |
Sean Moran
DFI | Director of Finance/CFO | 68 | 11/04/2014 |
Ian Hodgson
COO | Chief Operating Officer | 53 | 15/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Yuval Cohen
BRD | Director/Board Member | 51 | 11/04/2014 |
John Jenkins
BRD | Director/Board Member | 68 | 05/06/2018 |
Rachelle Jacques
CHM | Chairman | 54 | 15/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/8/26 | Free | Chief Technology Officer | 250,009 | 1.3494% | ||
| 11/8/26 | Buy | Executive/Senior Manager | 2,600 | 0.0140% | ||
| 7/8/26 | Sell | Chief Financial Officer | -12,000 | 0.0648% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.52% | +2.02% | +15.28% | +68.72% | 222M | |
| +1.03% | -2.05% | +39.28% | +94.60% | 68.87B | |
| +1.31% | +0.55% | +49.48% | +92.12% | 65.29B | |
| -0.15% | +4.36% | -11.72% | +380.39% | 27.65B | |
| +2.97% | -0.10% | +41.86% | +14.84% | 25.77B | |
| -0.73% | -7.27% | +2.87% | -15.33% | 26.08B | |
| +1.01% | +1.38% | +26.48% | -17.50% | 20.14B | |
| +3.45% | -14.83% | +225.22% | +389.50% | 17.03B | |
| +0.77% | -4.55% | -0.36% | +549.41% | 15.03B | |
| +1.76% | +7.91% | +61.34% | +167.76% | 14.5B | |
| Average | +1.11% | -2.23% | +44.97% | +172.45% | 28.06B | |
| Weighted average by Cap. | +1.17% | -2.12% | +42.84% | +142.62% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.11M 956K 897K 821K 1.53M 105M 1.54M 10.61M 4.13M 53.68M 4.17M 4.08M 173M | 2.4M 2.06M 1.94M 1.77M 3.31M 227M 3.34M 22.92M 8.93M 116M 9.01M 8.82M 373M |
| Net income | -116M -100M -93.88M -85.89M -160M -10.99B -162M -1.11B -432M -5.62B -437M -427M -18.09B | -135M -116M -109M -99.84M -186M -12.78B -188M -1.29B -503M -6.53B -508M -496M -21.03B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | USD 11.36 | -1.09% | 231,099 |
| 02/09/26 | USD 11.48 | +1.77% | 664,445 |
| 01/09/26 | USD 11.28 | +3.39% | 901,296 |
| 31/08/26 | USD 10.91 | 0.00% | 473,589 |
| 28/08/26 | USD 10.91 | -1.98% | 584,319 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRBP Stock
Select your edition
All financial news and data tailored to specific country editions
